SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
In the treatment of heart failure (HF), SGLT-2 inhibitor (SGLT-2i) can significantly improve
the clinical outcome and quality of life related to HF. The current data show that SGLT-2i is
effective and safe in improving HF outcomes in patients with CKD stage 4, but there is little
clinical evidence in patients with eGFR<20 ml/min/1.73 m2. Therefore, our research is
designed to confirm that SGLT2i can improve the outcome of HF in patients with chronic heart
failure with reduced ejection fraction (HFrEF) and chronic renal insufficiency
(eGFR<20ml/min/1.73m2).